Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipsen Acquisition Trifecta Raises North American Stakes

This article was originally published in The Pink Sheet Daily

Executive Summary

French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.
Advertisement

Related Content

White Paper Is Actually Branded Promotion, FDA Tells Ipsen
White Paper Is Actually Branded Promotion, FDA Tells Ipsen
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
Ipsen Confident in U.S. Neurology Push Despite Dysport Delay
FDA Review Of Ipsen’s Dysport Set Back Three Months
Vernalis Restructures, Gives Up U.S. Frova Rights To Increase Cash Reserves
Somatuline Autogel To Be Promoted By Tercica
Somatuline Autogel To Be Promoted By Tercica

Topics

Advertisement
UsernamePublicRestriction

Register

PS068030

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel